Clinical trials for the treatment of Kaposi sarcoma include the following medications:

- Pilot phase II trial with nelfinavir mesylate

- Phase II trial with recombinant EphB4-HAS fusion protein

- Phase I trial study with pomalidomide and pegylatedÂ liposomal doxorubicin hydrochloride

- Phase I/II trial study with Pomalidomide alone

- Pilot Phase II trial with tocilizumab with or without zidovudine and valganciclovir

A pilot study for the use of oraxol as a chemotherapeutic agent for the treatment of cutaneous angiosarcoma is set to begin July 2018.